piracetam has been researched along with Lassitude in 12 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors." | 9.13 | Levetiracetam for the treatment of hot flashes: a phase II study. ( Bardia, A; Barton, DL; Christensen, B; Kottschade, L; Loprinzi, CL; Sloan, JA; Smith, D; Tan, A; Thompson, S, 2008) |
| "The effect of piracetam, a cyclical derivative of GABA, was compared with that of a placebo in a double-blind study of 60 patients with post-concussional syndrome of 2-12 months' duration." | 9.04 | Piracetam in the treatment of post-concussional syndrome. A double-blind study. ( Hakamies, L; Hakkarainen, H, 1978) |
| "The antistress and antifatigue properties of a Chinese ginseng preparation were tested on Swiss albino mice, exposed to various experimental models of stress, and were compared with those of piracetam." | 7.66 | Antistress and antifatigue properties of Panax ginseng: comparison with piracetam. ( Banerjee, U; Izquierdo, JA, 1982) |
| "To examine the prevalence and clinical correlates of fatigue as an adverse event (AE) of antiepileptic drug (AED) treatment in patients with epilepsy." | 5.46 | Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event? ( Agrawal, N; Cock, HR; Lozsadi, DA; Mula, M; von Oertzen, TJ; Yogarajah, M, 2017) |
| "The objectives of this pilot trial were to assess the potential efficacy and safety of levetiracetam for the treatment of hot flashes, a major cause of morbidity among breast cancer survivors." | 5.13 | Levetiracetam for the treatment of hot flashes: a phase II study. ( Bardia, A; Barton, DL; Christensen, B; Kottschade, L; Loprinzi, CL; Sloan, JA; Smith, D; Tan, A; Thompson, S, 2008) |
| "The effect of piracetam, a cyclical derivative of GABA, was compared with that of a placebo in a double-blind study of 60 patients with post-concussional syndrome of 2-12 months' duration." | 5.04 | Piracetam in the treatment of post-concussional syndrome. A double-blind study. ( Hakamies, L; Hakkarainen, H, 1978) |
| "Levetiracetam is a frequently used drug in the therapy of partial onset, myoclonic and generalized tonic-clonic seizures." | 3.80 | A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient. ( Bahte, SK; Hiss, M; Kielstein, JT; Lichtinghagen, R, 2014) |
| "The antistress and antifatigue properties of a Chinese ginseng preparation were tested on Swiss albino mice, exposed to various experimental models of stress, and were compared with those of piracetam." | 3.66 | Antistress and antifatigue properties of Panax ginseng: comparison with piracetam. ( Banerjee, U; Izquierdo, JA, 1982) |
| "Levetiracetam is an effective antiepileptic drug in elderly individuals with cognitive impairment." | 2.75 | Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. ( Hepler, M; Irwin, D; Jenssen, S; Lippa, CF; Pillai, J; Rosso, A, 2010) |
" Adverse events reported after IV administration of LEV (| 2.72 | Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ( Daoust, A; Lu, ZS; Otoul, C; Ramael, S; Stockis, A; Toublanc, N; Troenaru, M, 2006) | |
| "To examine the prevalence and clinical correlates of fatigue as an adverse event (AE) of antiepileptic drug (AED) treatment in patients with epilepsy." | 1.46 | Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event? ( Agrawal, N; Cock, HR; Lozsadi, DA; Mula, M; von Oertzen, TJ; Yogarajah, M, 2017) |
| "Levetiracetam was independently associated with anger/aggression, nervousness/agitation, upset stomach, depression, and sleep disturbance; lamotrigine with nervousness/agitation, upset stomach, and difficulty concentrating; and valproic acid with upset stomach and shaky hands." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mula, M | 1 |
| von Oertzen, TJ | 1 |
| Cock, HR | 1 |
| Yogarajah, M | 1 |
| Lozsadi, DA | 1 |
| Agrawal, N | 1 |
| Bahte, SK | 1 |
| Hiss, M | 1 |
| Lichtinghagen, R | 1 |
| Kielstein, JT | 1 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Lippa, CF | 1 |
| Rosso, A | 1 |
| Hepler, M | 1 |
| Jenssen, S | 1 |
| Pillai, J | 1 |
| Irwin, D | 1 |
| Zakharov, VV | 1 |
| Rowbotham, MC | 1 |
| Manville, NS | 1 |
| Ren, J | 1 |
| Ramael, S | 1 |
| Daoust, A | 1 |
| Otoul, C | 1 |
| Toublanc, N | 1 |
| Troenaru, M | 1 |
| Lu, ZS | 1 |
| Stockis, A | 2 |
| Baulac, M | 1 |
| Brodie, MJ | 1 |
| Elger, CE | 1 |
| Krakow, K | 1 |
| Meyvisch, P | 1 |
| Falter, U | 1 |
| Thompson, S | 1 |
| Bardia, A | 1 |
| Tan, A | 1 |
| Barton, DL | 1 |
| Kottschade, L | 1 |
| Sloan, JA | 1 |
| Christensen, B | 1 |
| Smith, D | 1 |
| Loprinzi, CL | 1 |
| Banerjee, U | 1 |
| Izquierdo, JA | 1 |
| Hakkarainen, H | 1 |
| Hakamies, L | 1 |
| Radmayr, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus[NCT00603135] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn | ||
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| Trial Evaluating the Safety and Tolerability of Levetiracetam Intravenous 15-minute Infusion, Administered in b.i.d. Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 65 Years Suffering From Partial Onset Seizures[NCT00610454] | Phase 2 | 25 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
7 trials available for piracetam and Lassitude
| Article | Year |
|---|---|
Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment.
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Cognition; Cognition Disorders; Disease-Free Surviv | 2010 |
Pilot tolerability and effectiveness study of levetiracetam for postherpetic neuralgia.
Topics: Analgesics, Non-Narcotic; Calcium Channel Blockers; Fatigue; Female; Herpes Zoster; Humans; Levetira | 2003 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticonvulsants; Drug Administration Schedule; Drug T | 2007 |
Levetiracetam for the treatment of hot flashes: a phase II study.
Topics: Breast Neoplasms; Dizziness; Fatigue; Female; Hot Flashes; Humans; Levetiracetam; Middle Aged; Nootr | 2008 |
Piracetam in the treatment of post-concussional syndrome. A double-blind study.
Topics: Brain Concussion; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Fatigue; Headache; | 1978 |
[Modification of the decrease in efficiency in the middle period of life. Experiences with piracetam (Nootropil) in professional practice].
Topics: Adult; Age Factors; Aged; Anxiety; Clinical Trials as Topic; Drug Evaluation; Efficiency; Euphoria; | 1976 |
5 other studies available for piracetam and Lassitude
| Article | Year |
|---|---|
Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event?
Topics: Adult; Anticonvulsants; Epilepsy; Fatigue; Female; Humans; Levetiracetam; Male; Middle Aged; Piracet | 2017 |
A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient.
Topics: Aged; Anticonvulsants; Fatigue; Humans; Levetiracetam; Male; Metabolic Clearance Rate; Peritoneal Di | 2014 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
[Vinpotropil in the treatment of dyscirculatory encephalopathy with cognitive impairment without dementia].
Topics: Adult; Aged; Cognition Disorders; Dementia, Vascular; Dizziness; Drug Administration Schedule; Drug | 2010 |
Antistress and antifatigue properties of Panax ginseng: comparison with piracetam.
Topics: Adaptation, Psychological; Animals; Fatigue; Female; Humans; Male; Mice; Mice, Inbred Strains; Motor | 1982 |